Professor Iain J. McEwan, Dr Irene Hunter and Dr Craig Jamieson are exploring whether they can keep hormone therapy working for longer by targeting small drugs to a different, but equally important, part of the androgen receptor. This means that treatments will still work on variants that are missing the ‘switch’ that usually attaches to male hormones.
The team have already identified potential small drugs which could be used to stop the androgen receptor sending the messages telling the cell to grow. Alongside this, they plan to work with Elasmogen, a biotech company in Aberdeen, to develop new protein drugs called SoloMERs. The SoloMERs can be used in combination with the small drugs to lock the androgen receptor into place so that the small drugs have a better chance of working even more effectively.